Received Apr 30, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 3C423 | — |
Local reaction to Kinrix vaccine in one female patient.; itching; had swelling, itching, hot, and the right deltoid area was red; had swelling, itching, hot, and the right deltoid area was red; This non-serious case was reported by a consumer via call center representative and described the occurrence of swelling in a female patient who received DTPa-IPV (Kinrix) (batch number 3C423, expiry date 06-SEP-2027) for prophylaxis. On 08-APR-2026, the patient received Kinrix. On an unknown date, an unknown time after receiving Kinrix, the patient experienced swelling (Verbatim: Local reaction to Kinrix vaccine in one female patient.), pruritus (Verbatim: itching), feeling of warmth (Verbatim: had swelling, itching, hot, and the right deltoid area was red) and erythema (Verbatim: had swelling, itching, hot, and the right deltoid area was red). The outcome of the swelling, pruritus, feeling of warmth and erythema were unknown. It was unknown if the reporter considered the swelling, pruritus, feeling of warmth and erythema to be related to Kinrix and Kinrix Pre-Filled Syringe Device. It was unknown if the company considered the swelling, pruritus, feeling of warmth and erythema to be related to Kinrix and Kinrix Pre-Filled Syringe Device. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.; Sender's Comments: US-GSK-US2026055371:Same reporter